Revance Therapeutics, Inc.

Welcome to the Revanz Therapeutics first quarter 2023 financial results and corporate update conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star followed by one on your touchtone phone. If anyone has difficulty hearing the conference call, please press star zero for operator assistance. As a reminder, this call is being recorded today, Tuesday, May

or revance. Please go ahead. Thank you, operator.

Joining us on the call today from revance are Chief Executive Officer Mark Foley, President Dustin Suess, and Chief Financial Officer Toby Schilke. During this call, management will make forward-looking statements, including statements related to 2023 guidance, cash flow breakeven, operating leverage, blockbuster potential, our ability to draw on our debt and future revenue expenses, The market, our growth potential, our city approval and entry into the therapeutics market, our potential in other therapeutics indications, our commercial success, injector and consumer preferences and behavior, the efficacy and duration of Daxify, the benefits to us, practices, and consumers of our products and strategy, our customer base, the supply and manufacturing of Daxify, our sales team, our strategic partnerships, and our strategy, planned operations, and commercialization plans and timing. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and absurdities. Factors that could cause results to be different from these statements include factors that the company describes in the section titled Risk Factors in our annual report on Form 10-K, filed with the SEC on February 28, 2023, and our quarterly report on Form 10-Q, filed with the SEC today, May 9, 2023. Revance undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in its expectations. Also on today's call, we will present both GAAP and non-GAAP financial measures. A reconciliation of non-GAAP to GAAP measures is included in our earnings release. With that, I will turn the call over to Mark Foley, Chief Executive Officer of Revance. Mark?